FluoGuide A/S Feed

2025-11-24 11:05:00 Invitation to FluoGuide A/S (Nasdaq: FLUO) webcast on 27 November 2025

2025-11-05 17:27:00 FluoGuide strengthens leadership to advance clinical program and regulatory approval strategy 43,20 DKK | +3,35% | 0,24 MDKK

2025-11-05 17:22:00 FluoGuide convenes an extraordinary general meeting 43,20 DKK | +3,35% | 0,24 MDKK

2025-11-03 21:54:00 FluoGuide A/S issue warrants to board members, executive management and employees 41,80 DKK | +4,50% | 0,20 MDKK

2025-11-03 21:30:00 Share transfer and ownership restructuring – related party transaction 41,80 DKK | +4,50% | 0,20 MDKK

2025-11-03 21:28:00 FluoGuide A/S completes directed share issue of SEK 104 million 41,80 DKK | +4,50% | 0,20 MDKK

2025-11-03 17:43:00 FluoGuide A/S intends to carry out a directed share issue of approximately SEK 100 million 41,80 DKK | +4,50% | 0,20 MDKK

2025-10-28 13:47:00 FluoGuide in advanced negotiations on collaboration agreement with a world leading medical technology company 40,30 DKK | +2,03% | 1,01 MDKK

2025-10-06 09:05:00 Positive interim results from an investigator-initiated study of FG001 in meningioma and low-grade glioma surgery, presented at EANS 44,00 DKK | +10,00% | 1,33 MDKK

2025-09-16 11:01:00 FluoGuide receives positive FDA feedback on FG001 in high-grade glioma 39,10 DKK | 0,00% | 0,62 MDKK

2025-08-28 07:28:00 FluoGuide A/S publishes Interim Report H1 2025 40,90 DKK | +3,81% | 0,19 MDKK

2025-08-22 12:51:00 Invitation to FluoGuide A/S (Nasdaq: FLUO) webcast on 28 August 2025 40,30 DKK | -1,47% | 0,06 MDKK

2025-07-21 13:46:00 FluoGuide enters collaboration with global MedTech company Olympus 41,50 DKK | +1,72% | 0,67 MDKK

2025-07-03 14:56:00 Update on 2025 Outlook and Company progress 41,10 DKK | -2,61% | 0,12 MDKK

2025-06-10 09:02:00 FG001 clinical data in High-Grade Glioma is now published in Neurosurgery 40,90 DKK | +2,76% | 0,23 MDKK

2025-05-28 07:06:00 FluoGuide A/S publishes interim report for the period January – March 2025 - On track - first patients enrolled in CT-005 41,90 DKK | -2,78% | 0,21 MDKK

2025-04-15 10:28:00 FluoGuide includes first patient in phase II trial of FG001 for head and neck cancer 38,80 DKK | -0,26% | 0,37 MDKK

2025-03-27 15:50:00 Minutes from Annual General Meeting in FluoGuide A/S 38,00 DKK | -2,69% | 0,07 MDKK

2025-03-12 09:49:00 Notice of Annual General Meeting in FluoGuide A/S 41,10 DKK | +5,38% | 0,19 MDKK

2025-02-27 07:03:00 FluoGuide A/S publishes year-end and annual report for the fiscal year 2024 43,80 DKK | -4,37% | 0,12 MDKK

2025-02-27 07:00:00 FluoGuide A/S publishes interim report for the period January – December 2024 43,80 DKK | -4,37% | 0,12 MDKK

2025-01-15 16:34:00 FluoGuide A/S receives approval for phase II trial in head and neck cancer 45,10 DKK | +1,01% | 0,53 MDKK

2024-11-27 07:00:00 FluoGuide A/S publishes interim report for the period January – September 2024 36,90 DKK | +2,93% | 0,28 MDKK

2024-11-19 13:43:00 Publication of positive phase II clinical data for FG001 in patients with head and neck cancer 35,85 DKK | +4,52% | 0,21 MDKK

2024-11-12 18:23:00 FluoGuide A/S issue warrants to board member, CMO and CFO 33,90 DKK | -0,44% | 0,08 MDKK

2024-10-21 16:13:00 Roger Gunnarsson resigns as board member due to return to a full-time investment banking career, which precludes him from holding board position in FluoGuide 39,25 DKK | +2,35% | 0,26 MDKK

2024-10-07 13:13:00 FluoGuide A/S submits Clinical Trial Application for phase II trial in head and neck cancer 41,00 DKK | +0,37% | 0,21 MDKK

2024-08-29 08:55:00 FluoGuide A/S publishes interim report for the period January – June 2024 41,00 DKK | -1,20% | 0,34 MDKK

2024-08-26 09:05:00 FluoGuide appoints Jens Ellrich as Chief Medical Officer 41,35 DKK | +1,97% | 0,25 MDKK

2024-06-18 23:12:00 FluoGuide has completed a directed share issue to existing and new investors raising proceeds of SEK 60 million 46,80 DKK | +1,85% | 1,23 MDKK

2024-06-18 17:31:00 FluoGuide intends to carry out a directed share issue of approximately SEK 60 million 46,80 DKK | +1,85% | 1,23 MDKK

2024-05-30 08:51:00 FluoGuide A/S publishes interim report for the period January – March 2024 46,90 DKK | -1,26% | 0,20 MDKK

2024-05-27 09:40:00 FluoGuide selects laser system for photothermal cancer therapy with FG001 49,25 DKK | +1,23% | 0,36 MDKK

2024-03-20 14:25:00 Minutes from Annual General Meeting in FluoGuide A/S 51,00 DKK | -5,20% | 0,10 MDKK

2024-03-13 11:17:00 Chief Financial Officer (CFO) Ole Larsen buys shares 56,00 DKK | +3,32% | 0,65 MDKK

2024-03-12 12:12:00 FluoGuide enters collaboration within robot assisted head and neck cancer surgery with Intuitive Surgical, a world leading robotic-assisted surgery company 54,20 DKK | +12,68% | 0,98 MDKK

2024-03-01 12:41:00 Notice of Annual General Meeting in FluoGuide A/S 53,40 DKK | -2,55% | 0,52 MDKK

2024-02-28 08:10:00 FluoGuide A/S publishes year-end and annual report for the fiscal year 2023 54,20 DKK | -5,24% | 0,34 MDKK

2024-02-23 16:02:00 FluoGuide A/S issues warrants to CFO 56,00 DKK | +6,06% | 0,24 MDKK

2024-01-08 11:33:00 FluoGuide provides strategic update and outlines development plans towards commercialization of FG001 73,00 DKK | 0,00% | 0,60 MDKK

2023-12-09 16:17:00 Chief Development Officer (CDO) Grethe Nørskov Rasmussen sells shares 64,60 SEK | -6,38%

2023-12-08 09:55:00 FluoGuide raises SEK 12 million through exercise of warrants 69,00 DKK | +0,58% | 2,63 MDKK

2023-11-29 08:00:00 FluoGuide A/S publishes interim report for the period January – September 2023 66,40 DKK | -3,77% | 1,08 MDKK

2023-11-13 08:35:00 FluoGuide announces FG001 meets primary endpoint in phase llb trial in aggressive brain cancer 85,20 DKK | +0,24% | 0,79 MDKK

2023-11-06 10:01:00 FluoGuide confirms positive topline results from phase lla trial of FG001 in head & neck cancer at International Academy of Oral Oncology conference 88,00 DKK | +0,92% | 1,18 MDKK

2023-10-03 10:34:00 FluoGuide receives FDA Orphan Drug Designation for FG001 in high-grade glioma 88,60 DKK | +5,73% | 0,91 MDKK

2023-09-08 12:00:00 FluoGuide receives Danish award for the best share price performance since IPO 92,00 DKK | -0,22% | 0,19 MDKK

2023-09-07 14:32:00 Positive interim data from phase lla trial of FG001 in head & neck cancer presented as a case report at the World Molecular Imaging Congress in Prague 92,20 DKK | +4,77% | 0,54 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

FluoGuide A/S

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden